Phenotypes associated with this allele

• Allele Symbol: Pml⁺
• Allele Name: wild type
• Allele ID: MGI:2436279
• Summary: 7 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
ht1	Pml^tm1(PML/RARA)Ley/Pml^+	involves: C57BL/6	MGI:5014084
cn2	Pml^tm1(PML/RARA)Ley/Pml^+ Lyz2^tm1(cre)Ifo/Lyz2^+	involves: 129P2/OlaHsd * BALB/cJ * C57BL/6	MGI:5014088
cn3	Pml^tm1(PML/RARA)Ley/Pml^+ Tg(CMV-cre)1Cgn/0	involves: BALB/cJ * C57BL/6	MGI:5014086
cn4	Pml^tm1(PML/RARA)Ley/Pml^+ Tg(CAG-cre/Esr1*)5Amc/0	involves: BALB/cJ * C57BL/6 * CBA	MGI:5014087
cn5	Pml^tm1(PML/RARA)Ley/Pml^+ Tg(Mx1-cre)1Cgn/0	involves: C57BL/6 * CBA	MGI:5014085
cx6	Pml^tm1Ppp/Pml^+ Trp53^tm3.1Glo/Trp53^+	B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo	MGI:7485831
cx7	Pml^tm1Ppp/Pml^+ Trp53^tm3.1Glo/Trp53^tm3.1Glo	B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo	MGI:7485800

Genotype
MGI:5014084

ht1

• Allelic Composition: Pml^{tm1(PML/RARA)Ley}/Pml⁺
• Genetic Background: involves: C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

normal phenotype

no abnormal phenotype detected ( J:172024 )

• mice are viable with normal Mendelian inheritance and normal peripheral blood cell counts

Genotype
MGI:5014088

cn2

• Allelic Composition: Pml^{tm1(PML/RARA)Ley}/Pml⁺; Lyz2^tm1(cre)Ifo/Lyz2⁺
• Genetic Background: involves: 129P2/OlaHsd * BALB/cJ * C57BL/6

neoplasm

increased leukemia incidence ( J:172024 )

• one mouse exhibit rare leukemia with acute promyelocytic leukemia features

hematopoietic system

hematopoietic system phenotype ( J:172024 )

N • hematopoietic stem cells exhibit normal ex vivo self-renewal

Genotype
MGI:5014086

cn3

• Allelic Composition: Pml^{tm1(PML/RARA)Ley}/Pml⁺; Tg(CMV-cre)1Cgn/0
• Genetic Background: involves: BALB/cJ * C57BL/6

mortality/aging

prenatal lethality, complete penetrance ( J:172024 )

• no mice are produced

Genotype
MGI:5014087

cn4

• Allelic Composition: Pml^{tm1(PML/RARA)Ley}/Pml⁺; Tg(CAG-cre/Esr1*)5Amc/0
• Genetic Background: involves: BALB/cJ * C57BL/6 * CBA

hematopoietic system

enlarged spleen ( J:172024 )

• in one tamoxifen-treated mouse

decreased hematopoietic stem cell number ( J:172024 )

• small decrease in tamoxifen-treated mice

abnormal hematopoietic stem cell physiology ( J:172024 )

• hematopoietic stem cells from tamoxifen-treated mice exhibit in vitro self-renewal compared with control cells

• however, tamoxifen-treated mice do not exhibit myeloproliferative disease

immune system

enlarged spleen ( J:172024 )

• in one tamoxifen-treated mouse

growth/size/body

enlarged spleen ( J:172024 )

• in one tamoxifen-treated mouse

Genotype
MGI:5014085

cn5

• Allelic Composition: Pml^{tm1(PML/RARA)Ley}/Pml⁺; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: C57BL/6 * CBA

mortality/aging

prenatal lethality, complete penetrance ( J:172024 )

• no mice are produced

Genotype
MGI:7485831

cx6

• Allelic Composition: Pml^tm1Ppp/Pml⁺; Trp53^tm3.1Glo/Trp53⁺
• Genetic Background: B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo

mortality/aging

premature death ( J:317504 )

• median survival for the combined population of both males and females is 504 days, i.e., similar to that of mice heterozygous for Trp53 ^tm3.1Glo alone (499 days)

• median survival is 539 days for male mice and 488 days for female mice, indicating that loss of a single Pml allele does not reduce the mean survival of either male or female Trp53 ^tm3.1Glo heterozygotes

decreased tumor-free survival time ( J:317504 )

♂ • average survival of male mice that present with soft tissue sarcomas (42%) is 443 days

neoplasm

increased lymphoma incidence ( J:317504 )

• when tumors are segregated by sex, 33% of males and 42% of females exhibit lymphomas (expressed as a % disease/total number of mice)

• 43% of mice develop lymphomas (when expressed as a % of tumor type); 14% of mice develop two tumor types, lymphomas and sarcomas

• 38% of mice exhibit lymphomas when tumor incidence is evaluated per mouse, including those that succumb to EMH, and expressed as a % disease/total number of mice

increased T cell derived lymphoma incidence ( J:317504 )

• ~20% of lymphoid tumors are T-cell lymphomas

increased B cell derived lymphoma incidence ( J:317504 )

• immunophenotyping of lymphocytes from terminally resected tumors showed that ~80% of lymphoid tumors are B-cell lymphomas

increased carcinoma incidence ( J:317504 , J:317504 )

• 5% of mice develop carcinomas (when expressed as a % of tumor type) (J:317504)

• 4% of mice exhibit carcinomas (when expressed as a % disease/total number of mice) (J:317504)

♀ • when tumors are segregated by sex, 0% of males and 8% of females exhibit carcinomas (expressed as a % disease/total number of mice) (J:317504)

increased sarcoma incidence ( J:317504 )

• when tumors are segregated by sex, 42% of males and 17% of females exhibit soft-tissue sarcomas (expressed as a % disease/total number of mice)

• 52% of mice develop sarcomas (when expressed as a % of tumor type); 14% of mice develop two tumor types, lymphomas and sarcomas

• 46% of mice exhibit sarcomas (when expressed as a % disease/total number of mice)

increased osteosarcoma incidence ( J:317504 )

• when tumors are segregated by sex, 8% of males and 25% of females exhibit osteosarcomas (expressed as a % disease/total number of mice)

hematopoietic system

increased T cell derived lymphoma incidence ( J:317504 )

• ~20% of lymphoid tumors are T-cell lymphomas

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53 ^tm3.1Glo alone

extramedullary hematopoiesis ( J:317504 )

• when segregated by sex, 33% of males and 33% of females exhibit EMH

• 33% mice exhibit extramedullary hematopoiesis (EMH)

immune system

increased T cell derived lymphoma incidence ( J:317504 )

• ~20% of lymphoid tumors are T-cell lymphomas

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53 ^tm3.1Glo alone

liver/biliary system

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53 ^tm3.1Glo alone

growth/size/body

decreased body weight ( J:317504 )

• average body weight is significantly lower than that in C57BL/6 wild-type controls

hepatosplenomegaly ( J:317504 )

• mice exhibit less severe hepatosplenomegaly than mice heterozygous for Trp53 ^tm3.1Glo alone

skeleton

increased osteosarcoma incidence ( J:317504 )

• when tumors are segregated by sex, 8% of males and 25% of females exhibit osteosarcomas (expressed as a % disease/total number of mice)

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:317504 )

• ~20% of lymphoid tumors are T-cell lymphomas

Genotype
MGI:7485800

cx7

• Allelic Composition: Pml^tm1Ppp/Pml⁺; Trp53^tm3.1Glo/Trp53^tm3.1Glo
• Genetic Background: B6.129S7(Cg)-Pml^tm1Ppp Trp53^tm3.1Glo

mortality/aging

premature death ( J:317504 )

♂ • mean survival of male mice is 150 days, i.e., not significantly different from that in males homozygous for Trp53^tm3.1Glo alone (164.5 days)

prenatal lethality, incomplete penetrance ( J:317504 )

♀ • only 12% of females are born, indicating a severe reduction in female survival